FDA accelerates rectal cancer immunotherapy—plus AI safety re-think
LISTEN
Direct audio file (MP3)The global cure pipeline keeps compounding: there are 21,379 active cure-related trials, while in the last 24 hours new Wire signals (49) and new Cure research items (33) kept arriving at a steady clip. In cancer, the FDA approved an expanded use of dostarlimab (Jemperli) for a subset of locally advanced rectal cancer, potentially allowing some patients to avoid chemotherapy, radiation, and surgery—an outcome that matters because reducing treatment burden is part of durable clinical progress. Meanwhile, the Wire highlights early phase transitions in how AI is deployed: in government workflows it can generate more noise than time-savings, in security it shifts toward actively tracking targets, and in the biothreat domain the MI5 chief warns AI can change bioweapons risk beyond older containment assumptions. The restrained hope: even as the world recalibrates risks and practices, cure-relevant breakthroughs and trial activity keep moving—patient-focused decisions like this FDA step show the system can still convert speed into real benefit. The window is still open.
The FDA approved an expanded use of dostarlimab for a subset of locally advanced rectal cancer.
This matters because it may reduce or eliminate multiple standard modalities for some patients, while the Wire’s AI developments show how both healthcare and high-consequence risk landscapes can shift quickly.
Watch for how accelerated-approval claims translate into broader clinical uptake, because timing pressures are rising as trials remain high-count and new signals keep flowing—49 in the last 24 hours.